Unique SNP in CD44 intron 1 and its role in breast cancer development

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1263-1272

  Zhou, Juhua ^a   Nagarkatti, Prakash S ^a   Zhong, Yin ^a   Creek, Kim ^a   Zhang, Jiajia ^b   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; CD44; Gene polymorphism; Patient age; Tumor burden

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA ISOLATION; EXON; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; INTRON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BASE SEQUENCE; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTRONS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR BURDEN; YOUNG ADULT;

EID: 77953800009     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Peto J, Collins N, Barfoot R et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 97: 943-949, 1999.
2. Anglian Breast Cancer Study Group: Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83: 1301-1308, 2000.
3. Ford D, Easton DF, Stratton M et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689, 1998.
4. Antoniou AC and Easton DF: Models of genetic susceptibility to breast cancer. Oncogene 25: 5898-5905, 2006.
5. Thompson D and Easton D: The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 9: 221-236, 2004.
6. Dunning AM, Healey CS, Pharoah PD et al: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8: 843-854, 1999.
7. Kadouri L, Easton DF, Edwards S et al: CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 85: 36-40, 2001.
8. De Vivo I, Hankinson SE, Colditz GA et al: A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 63: 5236-5238, 2003.
9. Huggins GS, Wong JY, Hankinson SE et al: GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/A polymorphism. Cancer Res 66: 1384-1390, 2006.
10. Feigelson HS, Rodriguez C, Jacobs EJ et al: No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 13: 1084-1085, 2004.
11. Fernandez LP, Milne RL, Barroso E et al: Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer 119: 467-471, 2006.
12. Johnatty SE, Spurdle AB, Beesley J et al: Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies. Breast Cancer Res Treat 109: 91-99, 2008.
13. Cox A, Dunning AM, Garcia-Closas M et al: A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39: 352-358, 2007.
14. Pharoah PD, Tyrer J, Dunning AM et al: Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3: e42, 2007.
15. Easton DF, Pooley KA, Dunning AM et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093, 2007.
16. Bourguignon LY, Zhu D and Zhu H: CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 3: d637-49, 1998.
17. Seth A, Gote L, Nagarkatti M et al: T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. Proc Natl Acad Sci USA 88: 7877-7881, 1991. (Pubitemid 21915258)
18. Rafi A, Nagarkatti M and Nagarkatti PS: Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood 89: 2901-2908, 1997. (Pubitemid 27172577)
19. Chen D, McKallip RJ, Zeytun A et al: CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J Immunol 166: 5889-5897, 2001.
20. McKallip RJ, Fisher M, Do Y et al: Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem 278: 43818-43830, 2003.
21. McKallip RJ, Fisher M, Gunthert U et al: Role of CD44 and its v7 isoform in staphylococcal enterotoxin B-induced toxic shock: CD44 deficiency on hepatic mononuclear cells leads to reduced activation-induced apoptosis that results in increased liver damage. Infect Immun 73: 50-61, 2005.
22. Marhaba R and Zoller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 211-231, 2004.
23. Hill A, McFarlane S, Johnston PG et al: The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett 237: 1-9, 2006.
24. Gotte M and Yip GW: Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66: 10233-10237, 2006.
25. Dadi HK, Greaves AM, Cox DW et al: Identification of a polymorphism in human CD44. Nucleic Acids Res 19: 969, 1991.
26. Telen MJ, Udani M, Washington MK et al: A blood group-related polymorphism of CD44 abolishes a hyaluronan-binding consensus sequence without preventing hyaluronan binding. J Biol Chem 271: 7147-7153, 1996.
27. Park JW, Cai J, McIntosh I et al: High throughput SNP and expression analyses of candidate genes for non-syndromic oral clefts. J Med Genet 43: 598-608, 2006.
28. Peach RJ, Hollenbaugh D, Stamenkovic I et al: Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 122: 257-264, 1993. (Pubitemid 23188816)
29. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
30. Bernard-Gallon D, Bosviel R, Delort L et al: DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer 7: 36, 2008.
31. Terry MB, Gammon MD, Zhang FF et al: Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 13: 2053-2058, 2004.
32. Mitra AK, Singh N, Garg VK et al: Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to squamous cell carcinomas of the head and neck (SCCHN) and breast cancer in the north Indian population. J Exp Clin Cancer Res 28: 104, 2009.
33. Nagai K, Muto Y, Pomeranz Krummel DA et al: Structure and assembly of the spliceosomal snRNPs. Novartis Medal Lecture. Biochem Soc Trans 29: 15-26, 2001.
34. Black DL: Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72: 291-336, 2003.
35. Rafi-Janajreh AQ, Nagarkatti PS and Nagarkatti M: Role of CD44 in CTL and NK cell activity. Front Biosci 3: d665-671, 1998.
36. Smith ER, Adams SA, Das IP et al: Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. Cancer Epidemiol Biomarkers Prev 17: 2882-2890, 2008.
37. Carey LA, Perou CM, Livasy CA et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006.
38. Springwald A, Lattrich C, Seitz S et al: Single nucleotide polymorphisms in human gene ICB-1 and breast cancer susceptibility. Cancer Invest 27: 669-672, 2009.
39. Siddig A, Mohamed AO, Awad S et al: Estrogen receptor alpha gene polymorphism and breast cancer. Ann NY Acad Sci 1138: 95-107, 2008.
40. Siddig A, Mohamed AO, Kamal H et al: HER-2/neu I1e655Val polymorphism and the risk of breast cancer. Ann NY Acad Sci 1138: 84-94, 2008.